



UCB  
News

## U.S. Court of Appeals confirms validity of patent for UCB's Vimpat®

- **Court of Appeals for the Federal Circuit affirms Delaware District Court's decision**

**Brussels (Belgium), May 23rd, 2018 – 18.00 CEST** – UCB announces that in a decision released today, the Court of Appeals for the Federal Circuit (CAFC) has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551 related to Vimpat® (lacosamide), UCB's anti-epileptic drug.

"We are pleased with the CAFC decision," said Anna Richo UCB's Executive Vice President and General Counsel. "This confirms the strength of our intellectual property for Vimpat® and maintains UCB's exclusivity position until March 2022." This decision supports UCB's commitment to epilepsy patients and UCB's ability to deliver Vimpat® to patients.

### For further information

#### Investor Relations

Antje Witte,  
Investor Relations, UCB  
T +32.2.559.9414,  
antje.witte@ucb.com

Isabelle Ghellynck,  
Investor Relations, UCB  
T+32.2.559.9588,  
isabelle.ghellynck@ucb.com

#### Global Communications

France Nivelles,  
Global Communications, UCB  
T +32.2.559.9178,  
france.nivelles@ucb.com

Laurent Schots,  
Media Relations, UCB  
T+32.2.559.9264,  
laurent.schots@ucb.com

### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With approximately 7500 people operating in 40 countries, the company generated revenue of €4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

**Forward looking statements**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.